Comparison of Lu-177 obtained from two different commercial vendors for peptide receptor radionuclide therapy of neuroendocrine tumor patients: Preliminary results

被引：0
|
作者：
Lehmann, C. [1 ]
Prasad, V. [1 ]
Schuchardt, C. [1 ]
Mueller, D. [1 ]
Zachert, C. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zentralklin Bad Berka, Ctr PET CT, Clin Nucl Med, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S440 / S440
页数：1
相关论文
共 50 条
  • [1] Preliminary Results of Lu-177 DOTA-TATE Therapy in Patients with Neuroendocrine Tumor
    Hekimsoy, T.
    Isgoren, S.
    Gorur, G. Daglioz
    Demir, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S596 - S596
  • [2] Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S225
  • [3] Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours
    Kamaleshwaran, K.
    Sudhakar, N.
    Paulvannan, S.
    Vysakh, M.
    Shinto, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S722 - S722
  • [4] Serial Dosimetry in Peptide Receptor Radionuclide Therapy using Lu-177 DOTATATE or Lu-177 DOTATOC in the same Patient
    Schuchardt, C.
    Kulkarni, H.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S139 - S139
  • [5] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Yeokyeong Shin
    Bo Hyun Moon
    Baek-Yeol Ryoo
    Heung-Moon Chang
    Kyu-pyo Kim
    Yong Sang Hong
    Tae Won Kim
    Jin-Sook Ryu
    Yong-il Kim
    Changhoon Yoo
    Targeted Oncology, 2024, 19 : 41 - 49
  • [6] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Shin, Yeokyeong
    Moon, Bo Hyun
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Hong, Yong Sang
    Kim, Tae Won
    Ryu, Jin-Sook
    Kim, Yong-il
    Yoo, Changhoon
    TARGETED ONCOLOGY, 2024, 19 (01) : 41 - 49
  • [7] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Becx, Morticia N.
    Minczeles, Noemie S.
    Brabander, Tessa
    de Herder, Wouter W.
    Nonnekens, Julie
    Hofland, Johannes
    CANCERS, 2022, 14 (23)
  • [8] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET)
    Mc Ewan, A.
    Wieler, M.
    Makis, W.
    McMullen, T.
    Morrish, D.
    MacLeod, S.
    Schrader, L.
    Sawyer, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 94 - 94
  • [9] Absorbed Dose Values After Radionuclide Therapy with LU-177 DOTA TATE in Patients with Neuroendocrine Tumor
    Demir, M.
    Yeyin, N.
    Toklu, T.
    Uslu, L.
    Cavdar, I.
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S515 - S515
  • [10] Peptide receptor radionuclide therapy using somatostatin receptor antagonists: first results of biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC
    Schuchardt, Christiane
    Kulkarni, Harshad
    Singh, Aviral
    Mueller, Dirk
    Fani, Melpomeni
    Maecke, Helmut
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
12345